Predicting and Testing Helix-Mimetic Inhibitors of the p53-Mdm2 Interaction

Aberrant protein-protein interactions (PPIs) are found in many disease states. Consequently, there is a need for PPI inhibitors for use as research tools and pharmaceutical lead compounds. Computational methods could greatly assist with the search for new PPIs. Oligobenzamides are novel PPI inhibitors which can theoretically be produced to display any sequence of side chains. Understanding the nature of oligobenzamide binding is important for identification of the most efficient strategy of predicting oligobenzamide inhibitors. The prediction of oligobenzamide affinities using thermodynamic integration and implicit solvent methods is described. Affinities of oligobenzamides for Mdm2 predicted using implicit solvent methods bore a moderate correlation with measured affinities. Examination of MM-PBSA results using analysis of variance revealed that it is not necessary to run simulations with every member of a large combinatorial library in order to predict their relative affinities because within a particular binding site, the degree of interaction between the side chains is small. However, it could be useful to separate molecules based on their predicted binding pose because oligobenzamides can bind to Mdm2 in many different ways, depending on the choice of side chains. This insight will be valuable for future attempts to predict oligobenzamide affinities. The 1H-15N HSQC NMR spectrum peaks of 15N-labelled Mdm2 L33E were assigned to facilitate the future validation of binding poses. An oligoamide was shown using NMR to bind in the correct place. However, NMR testing revealed that oligobenzamides can aggregate in aqueous solution despite being soluble. A novel FRET-based method was also developed which can be used to test potential inhibitors with a low solubility and high absorbance during their development. It was adapted for a microwell plate to facilitate future high throughput screening and an assay involving Cherry-labelled Mdm2 was tested which could be developed into an in vivo assay in the future

DmWRNexo is a 3'aEuro"5' exonuclease:phenotypic and biochemical characterization of mutants of the Drosophila orthologue of human WRN exonuclease

The premature human ageing Werner's syndrome is caused by loss or mutation of the WRN helicase/exonuclease. We have recently identified the orthologue of the WRN exonuclease in flies, DmWRNexo, encoded by the CG7670 locus, and showed very high levels of mitotic recombination in a hypomorphic PiggyBac insertional mutant. Here, we report a novel allele of CG7670, with a point mutation resulting in the change of the conserved aspartate (229) to valine. Flies bearing this mutation show levels of mitotic recombination 20-fold higher than wild type. Molecular modelling suggests that D229 lies towards the outside of the molecule distant from the nuclease active site. We have produced recombinant protein of the D229V mutant, assayed its nuclease activity in vitro, and compared activity with that of wild type DmWRNexo and a D162A E164A double active site mutant we have created. We show for the first time that DmWRNexo has 3'aEuro"5' exonuclease activity and that mutation within the presumptive active site disrupts exonuclease activity. Furthermore, we show that the D229V mutant has very limited exonuclease activity in vitro. Using Drosophila, we can therefore analyse WRN exonuclease from enzyme activity in vitro through to fly phenotype, and show that loss of exonuclease activity contributes to genome instability